Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Curcumin for HSIL Cervical Neoplasia
NCT02944578Phase 2Terminated
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of curcumin in cervical intraepithelial neoplasia (CIN). Primary endpoint: Human Papillomavirus Related Molecular Target HPV E6/E7 Messenger Ribonucleic Acid Expression at 16 weeks. Started Nov 2017; status: terminated.
02
Drugs
curcumin
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02944578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944578.